Sökning: WFRF:(Richardus J H) >
Safety and immunoge...
-
Chlibek, Roman
(författare)
Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults : A phase II, randomized, controlled study
- Artikel/kapitelEngelska2014
Förlag, utgivningsår, omfång ...
-
Elsevier BV,2014
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-224365
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-224365URI
-
https://doi.org/10.1016/j.vaccine.2014.01.019DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Background: This study investigated the safety and immunogenicity of different formulations and schedules of a candidate subunit herpes zoster vaccine containing varicella-zoster virus glycoprotein E (gE) with or without the adjuvant system ASO1(B). Methods: In this phase II, single-blind, randomized, controlled study, adults aged >= 60 years (N = 714) received one dose of 100 mu g gE/AS01(B), two doses, two months apart, of 25, 50, or 100 mu g gE/AS01(B), or two doses of unadjuvanted 100 mu g gE/saline. Frequencies of CD4(+) T cells expressing >= 2 activation markers following induction with gE were measured by intracellular cytokine staining and serum anti-gE antibody concentrations by ELISA. Results: Frequencies of gE-specific CD4(+) T cells were >3-fold higher after two doses of all gE/AS01(B) formulations than after one dose of 100 mu g gE/AS01(B) or two doses of 100 mu g gE/saline. Frequencies were comparable after two doses of 25, 50, or 100 mu g gE/AS01g. Serum anti-gE antibody concentrations were comparable after two doses of 50 or 100 mu g gE/AS01(B) and higher than in the other groups. Immune responses persisted for at least 36 months. Reactogenicities of all gE/AS01(B) formulations were similar but greater than with gE/saline. Conclusions: The three formulations of gE/AS01(B) were immunogenic and well tolerated in adults aged >= 60 years. Two vaccinations with gE/AS01(B) induced higher immune responses than one and the dose of gE impacted humoral but not cellular immune responses (NCT00434577).
Ämnesord och genrebeteckningar
-
Varicella-zoster virus
-
Herpes zoster
-
Vaccine
-
Adjuvant
-
gE
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Smetana, Jan
(författare)
-
Pauksens, KarlisUppsala universitet,Infektionssjukdomar(Swepub:uu)karlpauk
(författare)
-
Rombo, Lars
(författare)
-
Van den Hoek, J. Anneke R.
(författare)
-
Richardus, Jan H.
(författare)
-
Plassmann, Georg
(författare)
-
Schwarz, Tino F.
(författare)
-
Ledent, Edouard
(författare)
-
Heineman, Thomas C.
(författare)
-
Uppsala universitetInfektionssjukdomar
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Vaccine: Elsevier BV32:15, s. 1745-17530264-410X1873-2518
Internetlänk
Hitta via bibliotek
-
Vaccine
(Sök värdpublikationen i LIBRIS)
Till lärosätets databas
- Av författaren/redakt...
-
Chlibek, Roman
-
Smetana, Jan
-
Pauksens, Karlis
-
Rombo, Lars
-
Van den Hoek, J. ...
-
Richardus, Jan H ...
-
visa fler...
-
Plassmann, Georg
-
Schwarz, Tino F.
-
Ledent, Edouard
-
Heineman, Thomas ...
-
visa färre...
- Artiklar i publikationen
-
Vaccine
- Av lärosätet
-
Uppsala universitet